Premium
O4–05–02: A phase II randomized, double‐blind, parallel group, 26‐week study of GSK‐3 inhibitor tideglusib in Alzheimer's disease (ARGO trial)
Author(s) -
Ser Teodoro,
Lovestone Simon,
BoadaRovira Mercè,
Dubois Bruno,
Hüll Michael,
Rinne Juha,
León Teresa
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.04.359
Subject(s) - tolerability , medicine , placebo , adverse effect , gastroenterology , randomized controlled trial , pathology , alternative medicine
a similar pattern to that described in Finland[4] . Possible environmental aetiological factors include a rural-urban effect [1], proximity to mining, selenium[5], or another factor, yet to be identified. 1. Russ et al. (2012) Int J Epidemiol 41:1012-32.2. Starr et al. (1997) Pyschiat Genet 7:147-52.3. Gat z et al. (2005) Neurobiol Aging 26:439-47.4. Sulkava et al. (1988) Regional differences in the prevalence of Alzheimer’s disease. In: Proceedings of the International Symposium on Alzheimer’s Disease, University of Kuopio, Finland.5. Parkman & Hultberg (2002) Occurrence and effects of selenium in the environment a literature review.